- $1.17bn
- $1.15bn
- $1.31bn
- 58
- 70
- 58
- 64
Annual income statement for Revelyst, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 1,322 | 1,339 | 1,309 |
| Cost of Revenue | |||
| Gross Profit | 397 | 377 | 373 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Unusual Expense / Income | |||
| Total Operating Expenses | 1,220 | 1,708 | 1,572 |
| Operating Profit | 102 | -368 | -263 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | 102 | -366 | -265 |
| Provision for Income Taxes | |||
| Net Income After Taxes | 78.4 | -337 | -242 |
| Net Income Before Extraordinary Items | |||
| Net Income | 78.4 | -337 | -242 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | 78.4 | -337 | -242 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | 1.34 | -1.47 | -1.55 |